Epizyme Inc (EPZM) - Strategic SWOT Analysis Review

August 2019 | 42 pages | ID: EAE382F0D55EN
GlobalData

Abstracts

Epizyme Inc (EPZM) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Epizyme, Inc. (Epizyme) is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. Its lead product candidate tazemetostat is a first-in-class EZH2 inhibitor finds application in hematological malignancies and solid tumors as a monotherapy and combination therapy in relapsed or refractory non-Hodgkin lymphoma. The company’s other pipeline products include EZM8266 for sickle cell disease; protein arginine methyltransferase (PRMT) inhibitors for solid tumors, B

cell lymphoma and blood cancer; Pinometostat for acute leukemia. The company develops products through proprietary drug discovery platform and collaborations with other companies. Epizyme is headquartered in Cambridge, Massachusetts, the US.

Epizyme Inc Key Recent Developments

Aug 09,2019: Epizyme reports business progress and second quarter 2019 results
Jul 22,2019: Epizyme strengthens leadership team with appointment of Paolo Tombesi as chief financial officer
May 06,2019: Epizyme provides business update and reports first quarter 2019 financial results
Feb 26,2019: Epizyme provides business update and reports fourth quarter and full year 2018 financial results
Nov 19,2018: Boehringer partners with Epizyme to develop new cancer therapies

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

SECTION 1 - ABOUT THE COMPANY

Epizyme Inc - Key Facts
Epizyme Inc - Key Employees
Epizyme Inc - Key Employee Biographies
Epizyme Inc - Major Products and Services
Epizyme Inc - History
Epizyme Inc - Company Statement
Epizyme Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Epizyme Inc - Business Description
R&D Overview
Epizyme Inc - Corporate Strategy
Epizyme Inc - SWOT Analysis
SWOT Analysis - Overview
Epizyme Inc - Strengths
Epizyme Inc - Weaknesses
Epizyme Inc - Opportunities
Epizyme Inc - Threats
Epizyme Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Epizyme Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Aug 09, 2019: Epizyme reports business progress and second quarter 2019 results
Jul 22, 2019: Epizyme strengthens leadership team with appointment of Paolo Tombesi as chief financial officer
May 06, 2019: Epizyme provides business update and reports first quarter 2019 financial results
Feb 26, 2019: Epizyme provides business update and reports fourth quarter and full year 2018 financial results
Nov 19, 2018: Boehringer partners with Epizyme to develop new cancer therapies
Nov 02, 2018: Epizyme reports third quarter 2018 financial results and Tazemetostat progress
Aug 02, 2018: Epizyme reports second quarter 2018 financial results and provides business updates
Jul 23, 2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer
May 08, 2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates
Mar 13, 2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Epizyme Inc, Key Facts
Epizyme Inc, Key Employees
Epizyme Inc, Key Employee Biographies
Epizyme Inc, Major Products and Services
Epizyme Inc, History
Epizyme Inc, Subsidiaries
Epizyme Inc, Key Competitors
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Epizyme Inc, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Epizyme Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Epizyme Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Takeda Pharmaceutical Co Ltd
Pfizer Inc
Novartis AG
Merck & Co Inc
Eisai Inc
Daiichi Sankyo Co Ltd
Constellation Pharmaceuticals Inc
Celgene Corp